These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 8010728)

  • 1. Biochemical parameters for prognostic evaluation in patients with breast cancer.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Sampognaro E; Meo S
    Anticancer Res; 1994; 14(2B):693-8. PubMed ID: 8010728
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PS2 in breast cancer--alternative or complementary tool to steroid receptor status? Evaluation of 446 cases.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Bari M; Leon AE; Vinante O; Bruscagnin G
    Br J Cancer; 1993 Aug; 68(2):374-9. PubMed ID: 8347494
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Value of immunohistochemical determination of receptors, tissue proteases, tumor suppressor proteins and proliferation markers as prognostic indicators in primary breast carcinoma].
    Göhring UJ; Scharl A; Ahr A
    Geburtshilfe Frauenheilkd; 1996 Apr; 56(4):177-83. PubMed ID: 8682282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Prognostic value of PS2 and cathepsin D in 710 human primary breast tumors: multivariate analysis.
    Foekens JA; van Putten WL; Portengen H; de Koning HY; Thirion B; Alexieva-Figusch J; Klijn JG
    J Clin Oncol; 1993 May; 11(5):899-908. PubMed ID: 8487052
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of steroid receptors, pS2 and cathepsin D on the outcome of elderly breast cancer patients: an exploratory investigation.
    Coradini D; Biganzoli E; Boracchi P; Bombardieri E; Seregni E; De Palo G; Martelli G; Di Fronzo G
    Int J Cancer; 1998 Aug; 79(4):305-11. PubMed ID: 9699519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of relapse and survival in breast cancer patients by pS2 protein status.
    Foekens JA; Rio MC; Seguin P; van Putten WL; Fauque J; Nap M; Klijn JG; Chambon P
    Cancer Res; 1990 Jul; 50(13):3832-7. PubMed ID: 2354435
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Cytosolic pS2 levels and cellular proliferation in ER-positive and PgR-positive infiltrating ductal carcinomas of the breast].
    Sánchez Salmón A; Argibay S; Arias JI; Ruibal A
    Rev Esp Med Nucl; 2005; 24(3):185-90. PubMed ID: 15847785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Steroid receptors, pS2 and cathepsin D in early clinically node-negative breast cancer.
    Stonelake PS; Baker PG; Gillespie WM; Dunn JA; Spooner D; Morrison JM; Bundred NJ; Oates GD; Lee MJ; Neoptolemos JP
    Eur J Cancer; 1994; 30A(1):5-11. PubMed ID: 8142164
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of steroid receptors, pS2 and cathepsin D on the outcome of N+ postmenopausal breast cancer patients treated with tamoxifen.
    Dittadi R; Biganzoli E; Boracchi P; Salbe C; Mione R; Gatti C; Gion M
    Int J Biol Markers; 1998; 13(1):30-41. PubMed ID: 9681297
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors.
    Marsigliante S; Biscozzo L; Correale M; Paradiso A; Leo G; Abbate I; Dragone CD; Storelli C
    Br J Cancer; 1994 Mar; 69(3):550-4. PubMed ID: 8123486
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Study of the cytosolic concentrations of the tissue poly-peptide specific (TPS) antigen in infiltrating ductal carcinomas of the breast. Positive relationship with hormone dependency and negative with cellular proliferation].
    Ruibal A; Arias JI; Resino C; Lapeña G; Schneider J; Tejerina A
    Rev Esp Med Nucl; 2001 Aug; 20(5):365-8. PubMed ID: 11470070
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinicopathological study of the expression of hsp27, pS2, cathepsin D and metallothionein in primary invasive breast cancer.
    Ioachim E; Tsanou E; Briasoulis E; Batsis Ch; Karavasilis V; Charchanti A; Pavlidis N; Agnantis NJ
    Breast; 2003 Apr; 12(2):111-9. PubMed ID: 14659340
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Inflammatory breast carcinoma: an immunohistochemical study using monoclonal anti-pHER-2/neu, pS2, cathepsin, ER and PR.
    Charpin C; Bonnier P; Khouzami A; Vacheret H; Andrac L; Lavaut MN; Allasia C; Piana L
    Anticancer Res; 1992; 12(3):591-7. PubMed ID: 1352440
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Correlation of cytosolic concentrations of ER, PS2, Cath-D, TPS, TK and cAMP in primary breast carcinomas.
    Kausitz J; Kuliffay P; Pecen L; Eben K; Puterová B
    Neoplasma; 1994; 41(6):331-6. PubMed ID: 7870216
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oestrogen receptor, progesterone receptor, pS2, ERD5, HSP27 and cathepsin D in invasive ductal breast carcinomas.
    Hurlimann J; Gebhard S; Gomez F
    Histopathology; 1993 Sep; 23(3):239-48. PubMed ID: 8225242
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tissue polypeptide antigen in breast cancer cytosol: a new effective prognostic indicator.
    Gion M; Mione R; Pappagallo GL; Gatti C; Nascimben O; Brandes A; Vinante O; Bruscagnin G
    Eur J Cancer; 1992; 29A(1):66-9. PubMed ID: 1445748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correlation between pS2 protein positivity, steroid receptor status and other prognostic factors in breast cancer.
    Racca S; Conti G; Pietribiasi F; Stramignoni D; Tampellini M; Valetto MR; Ghezzo F; Di Carlo F
    Int J Biol Markers; 1995; 10(2):87-93. PubMed ID: 7561244
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prognostic significance of the estrogen-regulated proteins, cathepsin-D and pS2, in breast cancer.
    Fulco RA; Petix M; Salimbeni V; Torre EA
    Minerva Med; 1998; 89(1-2):5-10. PubMed ID: 9561019
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cathepsin-D in primary breast cancer: prognostic evaluation involving 2810 patients.
    Foekens JA; Look MP; Bolt-de Vries J; Meijer-van Gelder ME; van Putten WL; Klijn JG
    Br J Cancer; 1999 Jan; 79(2):300-7. PubMed ID: 9888472
    [TBL] [Abstract][Full Text] [Related]  

  • 20. pS2 expression and response to hormonal therapy in patients with advanced breast cancer.
    Schwartz LH; Koerner FC; Edgerton SM; Sawicka JM; Rio MC; Bellocq JP; Chambon P; Thor AD
    Cancer Res; 1991 Jan; 51(2):624-8. PubMed ID: 1985778
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.